Success Metrics

Completion Rate
0%(0/2)
Active Trials
3(43%)
Terminated
2(29%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_1
5
71%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Terminated(2)
Other(2)

Detailed Status

Recruiting3
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

recruiting343%
terminated229%
unknown229%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_1

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

NCT06821503
terminatedphase_1

Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

NCT06320080
terminatedphase_1

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

NCT05975645
unknownphase_1

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

NCT06010901
recruitingphase_2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

NCT05494060
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06821503Phase 1

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Recruiting
NCT06320080Phase 1

Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

Terminated
NCT05975645Phase 1

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Terminated
NCT06010901Phase 1

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Unknown
NCT05494060Phase 2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Recruiting
NCT06081673Phase 2

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Recruiting
NCT05400876Phase 1

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7